Skip to content
2000
image of Functional Roles of Non-Coding RNAs in Graves' Disease

Abstract

Graves' disease (GD) is a disorder marked by an enlarged and overactive thyroid gland (Graves' hyperthyroidism), ocular abnormalities (Graves' orbitopathy; GO), and localized dermopathy (pretibial myxoedema; PTM). It is recognized as the most common cause of hyperthyroidism worldwide. Patients with GD most frequently exhibit elevated thyroid hormone secretion from thyroid cells as a result of autoantibodies acting as thyroid-stimulating hormone receptor (TSHR) agonists. Numerous investigations have examined the elements that contribute to the pathogenesis of GD, focusing on different components, such as molecular factors like non-coding RNAs (ncRNAs). NcRNAs represent a type of RNA transcript that, while not encoding proteins, are essential in the regulation of numerous aspects of cellular biology. NcRNAs include major groups, such as circular RNAs (circRNAs), long non-coding RNAs (lncRNAs), and small non-coding RNAs (sncRNAs), all of which are garnering increasing interest in the scientific community. This review will provide a comprehensive analysis of the function of ncRNAs in the development, diagnosis, and treatment of GD, and investigate the latest research in this area.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmm/10.2174/0115665240380518251113092158
2026-02-13
2026-02-27

  • From This Site

    /content/journals/cmm/10.2174/0115665240380518251113092158
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Grixti L. Lane L.C. Pearce S.H. The genetics of Graves’ disease. Rev. Endocr. Metab. Disord. 2024 25 1 203 214 10.1007/s11154‑023‑09848‑8 38108994
    [Google Scholar]
  2. Phagoora J. Bakilwal S. Hamzehpour A.S. Graves disease-A comprehensive review. Physician’s. J. Med. 2024 3 1 6 11 10.55070/137w7361
    [Google Scholar]
  3. Lanzolla G. Marinò M. Menconi F. Graves disease: Latest understanding of pathogenesis and treatment options. Nat. Rev. Endocrinol. 2024 20 11 647 660 10.1038/s41574‑024‑01016‑5 39039206
    [Google Scholar]
  4. Davies T.F. Andersen S. Latif R. Graves’ disease. Nat. Rev. Dis. Primers 2020 6 1 52 10.1038/s41572‑020‑0184‑y 32616746
    [Google Scholar]
  5. Perros P. Hegedüs L. Bartalena L. Graves’ orbitopathy as a rare disease in Europe: A European Group on Graves’ Orbitopathy (EUGOGO) position statement. Orphanet J. Rare Dis. 2017 12 1 72 10.1186/s13023‑017‑0625‑1 28427469
    [Google Scholar]
  6. Fatourechi V. Thyroid dermopathy and acropachy. In: Graves’ Disease. New York Springer 2015 195 212 10.1007/978‑1‑4939‑2534‑6_15
    [Google Scholar]
  7. Koren S. Shteinshnaider M. Or K. Cantrell D. Benbassat C.A. Koren R.A. 2017 survey of the clinical practice patterns in the management of relapsing Graves disease. Endocr. Pract. 2019 25 1 55 61 10.4158/EP‑2018‑0386 30383500
    [Google Scholar]
  8. Ghasemian M. Zehtabi M. Dari M.A.G. The emerging roles of long non-coding RNA (lncRNA) H19 in gynecologic cancers. BMC Cancer 2024 24 1 4 10.1186/s12885‑023‑11743‑z 38166752
    [Google Scholar]
  9. Azizidoost S. Khojasteh Pour F. Najafi S. The role of long non-coding RNAs in the pathogenesis of essential hypertension. Curr. Signal Transduct. Ther. 2024 19 2 110324227859 10.2174/0115743624283095240308072648
    [Google Scholar]
  10. Matsui M. Corey D.R. Non-coding RNAs as drug targets. Nat. Rev. Drug Discov. 2017 16 3 167 179 10.1038/nrd.2016.117 27444227
    [Google Scholar]
  11. Jang S.Y. Park S.J. Chae M.K. Lee J.H. Lee E.J. Yoon J.S. Role of microRNA-146a in regulation of fibrosis in orbital fibroblasts from patients with Graves’ orbitopathy. Br. J. Ophthalmol. 2018 102 3 407 414 10.1136/bjophthalmol‑2017‑310723 29101123
    [Google Scholar]
  12. Jang S.Y. Chae M.K. Lee J.H. Lee E.J. Yoon J.S. Role of miR-146a in the regulation of inflammation in an in vitro model of Graves’ orbitopathy. Invest. Ophthalmol. Vis. Sci. 2016 57 10 4027 4034 10.1167/iovs.16‑19213 27494344
    [Google Scholar]
  13. Eissa M.G. Artlett C.M. The microRNA miR-155 is essential in fibrosis. Noncoding RNA 2019 5 1 23 10.3390/ncrna5010023 30871125
    [Google Scholar]
  14. Wu L. Zhou R. Diao J. Differentially expressed circular RNAs in orbital adipose/connective tissue from patients with thyroid-associated ophthalmopathy. Exp. Eye Res. 2020 196 108036 10.1016/j.exer.2020.108036 32376473
    [Google Scholar]
  15. Quinn J.J. Chang H.Y. Unique features of long non-coding RNA biogenesis and function. Nat. Rev. Genet. 2016 17 1 47 62 10.1038/nrg.2015.10 26666209
    [Google Scholar]
  16. Huang A. Zheng H. Wu Z. Chen M. Huang Y. Circular RNA-protein interactions: Functions, mechanisms, and identification. Theranostics 2020 10 8 3503 3517 10.7150/thno.42174 32206104
    [Google Scholar]
  17. Yin L. Zeng C. Yao J. Shen J. Emerging roles for noncoding RNAs in autoimmune thyroid disease. Endocrinology 2020 161 8 bqaa053 10.1210/endocr/bqaa053 32270194
    [Google Scholar]
  18. Gupta R.A. Shah N. Wang K.C. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010 464 7291 1071 1076 10.1038/nature08975 20393566
    [Google Scholar]
  19. Wu G. Cai J. Han Y. LincRNA-p21 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis, and atherosclerosis by enhancing p53 activity. Circulation 2014 130 17 1452 1465 10.1161/CIRCULATIONAHA.114.011675 25156994
    [Google Scholar]
  20. Morán I. Akerman İ. van de Bunt M. Human β cell transcriptome analysis uncovers lncRNAs that are tissue-specific, dynamically regulated, and abnormally expressed in type 2 diabetes. Cell Metab. 2012 16 4 435 448 10.1016/j.cmet.2012.08.010 23040067
    [Google Scholar]
  21. Yao Q. Wang X. He W. Circulating microRNA-144-3p and miR-762 are novel biomarkers of Graves’ disease. Endocrine 2019 65 1 102 109 10.1007/s12020‑019‑01884‑2 30949910
    [Google Scholar]
  22. Hiratsuka I. Yamada H. Munetsuna E. Hashimoto S. Itoh M. Circulating microRNAs in Graves’ disease in relation to clinical activity. Thyroid 2016 26 10 1431 1440 10.1089/thy.2016.0062 27610819
    [Google Scholar]
  23. Zhang D. Qiu X. Li J. Zheng S. Li L. Zhao H. MiR-23a-3p-regulated abnormal acetylation of FOXP3 induces regulatory T cell function defect in Graves’ disease. Biol. Chem. 2019 400 5 639 650 10.1515/hsz‑2018‑0343 30391932
    [Google Scholar]
  24. Yin X. Ge J. Ge X. MiR‐363‐5p modulates regulatory T cells through STAT4‐HSPB1‐Notch1 axis and is associated with the immunological abnormality in Graves’ disease. J. Cell. Mol. Med. 2021 25 19 9364 9377 10.1111/jcmm.16876 34431214
    [Google Scholar]
  25. Chen J. Tian J. Tang X. MiR-346 regulates CD4+CXCR5+ T cells in the pathogenesis of Graves’ disease. Endocrine 2015 49 3 752 760 10.1007/s12020‑015‑0546‑5 25666935
    [Google Scholar]
  26. Liu Y. Wang X. Luan W. MiR-29a-3p negatively regulates circulating Tfh memory cells in patients with Graves’ disease by targeting ICOS. Immunol. Res. 2023 71 2 173 184 10.1007/s12026‑022‑09333‑5 36322282
    [Google Scholar]
  27. Chen X. Huang F. Qi Y. Serum and thyroid tissue level of let-7b and their correlation with TRAb in Graves’ disease. J. Transl. Med. 2018 16 1 188 10.1186/s12967‑018‑1565‑9 29976201
    [Google Scholar]
  28. Bernecker C. Halim F. Lenz L. microRNA expressions in CD4+ and CD8+ T-cell subsets in autoimmune thyroid diseases. Exp. Clin. Endocrinol. Diabetes 2014 122 2 107 112 10.1055/s‑0033‑1361088 24554510
    [Google Scholar]
  29. Sawicka B. Sulewska A. Kulczyńska-Przybik A. Potential role of selected miRNAs in the pathogenesis of autoimmune thyroid diseases in children and adolescents. Biomedicines 2024 12 4 731 10.3390/biomedicines12040731 38672087
    [Google Scholar]
  30. Qi Y. Zhou Y. Chen X. MicroRNA-4443 causes CD4+ T cells dysfunction by targeting TNFR-associated factor 4 in Graves’ disease. Front. Immunol. 2017 8 1440 10.3389/fimmu.2017.01440 29163513
    [Google Scholar]
  31. Zheng L. Zhuang C. Wang X. Ming L. Serum miR‐146a, miR‐155, and miR‐210 as potential markers of Graves’ disease. J. Clin. Lab. Anal. 2018 32 2 22266 10.1002/jcla.22266 28569050
    [Google Scholar]
  32. Liu R. Ma X. Xu L. Differential microRNA expression in peripheral blood mononuclear cells from Graves’ disease patients. J. Clin. Endocrinol. Metab. 2012 97 6 E968 E972 10.1210/jc.2011‑2982 22456620
    [Google Scholar]
  33. Qin Q. Wang X. Yan N. Aberrant expression of miRNA and mRNAs in lesioned tissues of Graves’ disease. Cell. Physiol. Biochem. 2015 35 5 1934 1942 10.1159/000374002 25871842
    [Google Scholar]
  34. Inoue Y. Watanabe M. Inoue N. Associations of single nucleotide polymorphisms in precursor-microRNA (miR)-125a and the expression of mature miR-125a with the development and prognosis of autoimmune thyroid diseases. Clin. Exp. Immunol. 2014 178 2 229 235 10.1111/cei.12410 24990808
    [Google Scholar]
  35. Yin Q. Jin Z. Zhou Y. lncRNA:mRNA expression profile in CD4+ T cells from patients with Graves’ disease. Endocr. Connect. 2020 9 12 1202 1211 10.1530/EC‑20‑0373 33112836
    [Google Scholar]
  36. Christensen N.J. Habekost G. Bratholm P. Decrease in TSH receptor autoantibodies during antithyroid treatment: Relationship with a long noncoding Heg RNA and Cdk1 mRNA in mononuclear cells. ISRN Endocrinol. 2011 2011 1 1 4 10.5402/2011/287052 22363873
    [Google Scholar]
  37. Yao Q. Song Z. Wang B. Jia X. Song R. Zhang J. Identification of lncRNA and mRNA expression profile in relapsed Graves’ disease. Front. Cell Dev. Biol. 2021 9 756560 10.3389/fcell.2021.756560 34926448
    [Google Scholar]
  38. Liu Y. Zou J. Xu J. Comprehensive analysis of lncRNA expression profile and the potential Role of ENST00000604491 in Graves’ disease. J. Immunol. Res. 2022 2022 1 1 13 10.1155/2022/8067464 35509980
    [Google Scholar]
  39. Huang F.J. Liu Y.L. Wang J. Zhou Y.Y. Zhao S.Y. Qin G.J. LncRNA RUNX1-IT1 affects the differentiation of Th1 cells by regulating NrCAM transcription in Graves’ disease. Cell Cycle 2022 21 9 921 933 10.1080/15384101.2022.2034431 35220890
    [Google Scholar]
  40. Sun Y. Wang W. Tang Y. Microarray profiling and functional analysis of differentially expressed plasma exosomal circular RNAs in Graves’ disease. Biol. Res. 2020 53 1 32 10.1186/s40659‑020‑00299‑y 32727578
    [Google Scholar]
  41. Jiang Z. Huang L. Chen L. Circular RNA profile in Graves’ disease and potential function of hsa_circ_0090364. Endocr. Connect. 2022 11 11 220030 10.1530/EC‑22‑0030 36018563
    [Google Scholar]
  42. Liu Y. Wang X. Xu J. Circular RNA CircZNF644 facilitates circulating follicular helper T cells response in patients with Graves’ disease. J. Immunol. Res. 2024 2024 1 9527268 10.1155/2024/9527268 38966668
    [Google Scholar]
  43. Jiang Z. Huang L. Cai H. Circular RNA circPHF16 enhances IL-17A expression and secretion by sequestering miR-378a-3p to activate the IL6ST axis in Graves’ disease. Cytokine 2024 181 156681 10.1016/j.cyto.2024.156681 38963941
    [Google Scholar]
  44. Shao X. Wang B. Mu K. Key gene co-expression modules and functional pathways involved in the pathogenesis of Graves’ disease. Mol. Cell. Endocrinol. 2018 474 252 259 10.1016/j.mce.2018.03.015 29614339
    [Google Scholar]
  45. Liu H. Tang T. Descriptive pan-cancer genetic analysis of disulfidptosis-related gene set. bioRxiv 2023 2023.02.25.529997
    [Google Scholar]
  46. Liu H. Tang T. Pan-cancer genetic analysis of cuproptosis and copper metabolism-related gene set. Front. Oncol. 2022 12 952290 10.3389/fonc.2022.952290 36276096
    [Google Scholar]
  47. Rasteh A.M. Liu H. Wang P. Pan-cancer genetic profiles of mitotic DNA integrity checkpoint protein kinases. bioRxiv 2024 2024.11.15.623822
    [Google Scholar]
  48. Duan L. Zhao M. Wei H. Bioinformatics analysis of the association between miR-942-5p–induced downregulation of PIEZO-type mechanosensitive ion channel component 1 and poor prognosis in non–small cell lung cancer mediated by the mitogen-activated protein kinase pathway signaling pathway. Oncol. Transl. Med. 2024 10 6 272 280 10.1097/ot9.0000000000000060
    [Google Scholar]
  49. Zhang L. Masetti G. Colucci G. Combining micro-RNA and protein sequencing to detect robust biomarkers for Graves’ disease and orbitopathy. Sci. Rep. 2018 8 1 8386 10.1038/s41598‑018‑26700‑1 29849043
    [Google Scholar]
  50. Nguyen L.D. Chau R.K. Krichevsky A.M. Small molecule drugs targeting non-coding RNAs as treatments for Alzheimer’s disease and related dementias. Genes 2021 12 12 2005 10.3390/genes12122005 34946953
    [Google Scholar]
  51. Zhang H. Zhou Y. Yu B. Multi-omics approaches to discover biomarkers of thyroid eye disease: A systematic review. Int. J. Biol. Sci. 2024 20 15 6038 6055 10.7150/ijbs.103977 39664569
    [Google Scholar]
  52. Liu H. Li Y. Karsidag M. Tu T. Wang P. Technical and biological biases in bulk transcriptomic data mining for cancer research. J. Cancer 2025 16 1 34 43 10.7150/jca.100922 39744578
    [Google Scholar]
/content/journals/cmm/10.2174/0115665240380518251113092158
Loading
Functional Roles of Non-Coding RNAs in Graves' Disease
Bentham Science Publishers ; https://doi.org/10.2174/0115665240380518251113092158
/content/journals/cmm/10.2174/0115665240380518251113092158
/content/journals/cmm/10.2174/0115665240380518251113092158
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: thyroid gland ; hyperthyroidism ; TSHR ; ncRNAs ; Graves' disease ; diagnosis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test